Multivalent nanoparticle-based vaccines

Patent metadata

Field	Value
Publication number	US-11191727-B2
Application number	US-201515540898-A
Country	US
Kind code	B2
Filing date	Dec 31, 2015
Priority date	Dec 31, 2014
Publication date	Dec 7, 2021
Grant date	Dec 7, 2021

Abstract

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents. Also provided are specific fusion proteins, nucleic acid molecules encoding such fusion proteins and methods of using nanoparticles of the invention to vaccinate individuals.

First claim

What is claimed:

1. A nanoparticle comprising at least four species of self-assembling fusion proteins, each fusion protein comprising a self-assembling, monomeric ferritin protein joined to an amino acid sequence consisting of an immunogenic portion of the receptor binding domain (RBD) from an influenza virus hemagglutinin (HA) protein, and optionally one or more protease sites and/or one or more linker sequences,
wherein the immunogenic portion in each species of self-assembling fusion protein differs from the immunogenic portions in the other species of self-assembling fusion proteins by at least one amino acid;
wherein the nanoparticle displays on its surface, the immunogenic portions of the at least four species of self-assembling fusion proteins; and,
wherein each fusion protein comprises an amino acid sequence at least 80% identical to SEQ ID NO:97.

2. A nanoparticle comprising at least two species of self-assembling fusion proteins, each fusion protein comprising a self-assembling, monomeric subunit protein joined to an amino acid sequence consisting of an immunogenic portion of the receptor binding domain (RBD) from an influenza virus hemagglutinin (HA) protein, and optionally one or more protease sites and/or one or more linker sequences,
wherein the immunogenic portion in each species of self-assembling fusion protein differs from the immunogenic portions in the other species of self-assembling fusion proteins by at least one amino acid;
wherein the nanoparticle displays on its surface, the immunogenic portions of the at least two species of self-assembling fusion proteins; and
wherein each fusion protein comprises an amino acid sequence at least 80% identical to SEQ ID NO:97.

3. A kit comprising the nanoparticle of claim 1 .

Assignees

• The Usa As Represented By The Sec Dep Of Health And Human Services
• Us Health

Inventors

• Graham Barney S
• Kanekiyo Masaru
• Yassine Hadi M

Classifications

• C12N2760/16171

  Demonstrated in vivo effect · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title

• A61K2039/575

  humoral response · CPC title